Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Cypralis receives $524,000 in ADDF grant
June 2017
SHARING OPTIONS:

CAMBRIDGE, U.K.—Cypralis Limited recently announced that it had received $524,000 in funding from the Alzheimer’s Drug Discovery Foundation, which the company intends to use to support its ongoing collaboration with Janssen Pharmaceuticals Inc. to develop new cyclophilin inhibitors for neurodegenerative diseases. Cypralis and Janssen are working on a joint research program to generate a new class of central nervous system (CNS)-penetrant, selective inhibitors of cyclophilin D that can target degenerative diseases, including CNS degeneration. This funding will allow Cypralis to extend hit-to-lead medicinal chemistry and expand its library of novel brain-penetrant cyclophilin inhibitors as well.
 
Dr. Michael Peel, chief scientific officier of Cypralis, commented that: “If data from the ADDF funding is encouraging, Cypralis would expect to initiate a lead optimization campaign in early 2018 with the goal of generating a novel preclinical candidate for this extremely challenging and devastating disease.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.